Associated tags: FDA, Aquablation therapy, Urology, Silicon, Health, BPH, Pharmaceutical industry
Locations: REDWOOD CITY, CA, US, HYATT, TX
FDA,
Bleeding,
Safety,
Risk,
American Urological Association,
Abstract,
LUTS,
ASC,
Surgeon,
TURP,
International Prostate Symptom Score,
Patient,
SDD,
AUA,
Health,
Patient satisfaction,
Clinical trial,
SAN,
BPH,
IPSS,
Benign prostatic hyperplasia The results were presented this past weekend at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas.
Key Points:
- The results were presented this past weekend at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas.
- “The data presented at AUA confirm the safety and long-term durability of Aquablation therapy in treating men with symptomatic benign prostatic hyperplasia, regardless of prostate size or shape," said Reza Zadno, CEO of PROCEPT BioRobotics.
- Three surgeons at Potomac Urology collected data on 812 consecutive men treated with Aquablation therapy.
- We have treated more than 800 men with Aquablation therapy and feel that the results truly speak for themselves,” said Shawn Marhamati, MD, MS, at Potomac Urology.
Urology,
Safety,
American Urological Association,
Abstract,
ASC,
LUTS,
Surgeon,
TURP,
Patient,
AMVETS,
SDD,
AUA,
Robotics,
Biorobotics,
Health,
USAV,
Clinical trial,
SAN,
BPH PROCEPT BioRobotics is exhibiting at booth #1429 and will be conducting hands-on workshops and surgeon presentations throughout the meeting.
Key Points:
- PROCEPT BioRobotics is exhibiting at booth #1429 and will be conducting hands-on workshops and surgeon presentations throughout the meeting.
- “The growing body of real-world clinical evidence on Aquablation therapy is reflected by the extensive range of presentations being showcased at the AUA,” said Reza Zadno, CEO of PROCEPT BioRobotics.
- The continued momentum and interest in Aquablation therapy are a testament to our unwavering commitment to advancing innovative, safe and effective treatment options for patients.”
Registered attendees can access the full list of Aquablation therapy presentations here.
- PROCEPT BioRobotics will sponsor additional satellite events during AUA at both the Henry B. Gonzalez Convention Center and off-site, including:
SAN JOSE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, May 3, 2024, at the Grand Hyatt Hotel in San Antonio, TX at the American Urological Association Annual Meeting from 8:00am to 9:30am Central Time.
Key Points:
- SAN JOSE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, May 3, 2024, at the Grand Hyatt Hotel in San Antonio, TX at the American Urological Association Annual Meeting from 8:00am to 9:30am Central Time.
- Members of PROCEPT BioRobotics’ management team presenting include:
Barry Templin – Executive VP, Technology and Clinical Development
Clinical perspectives will also be provided by the following physicians:
A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the Company’s website at https://ir.procept-biorobotics.com/.
- The webcast will be archived and available for replay for at least 90 days after the event.
Key Points:
- Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com .
- An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com .
- Each webcast will be available for replay for at least 90 days after the event.
- The Company also announced today that members of management will present at the upcoming Bank of America 2024 Health Care Conference in Las Vegas.
Retrieved on:
Tuesday, February 27, 2024
International,
SAN,
Total,
Research,
Investment,
Marketing,
Growth,
BPH,
GAAP,
Urology,
Health,
Interest,
Video game Gross margin for the fourth quarter 2023 was 49% compared to 45% in the prior year period.
Key Points:
- Gross margin for the fourth quarter 2023 was 49% compared to 45% in the prior year period.
- Operating expenses in the fourth quarter of 2023 were $50.8 million, compared with $35.7 million in the prior year period.
- Net loss was $27.5 million for the fourth quarter of 2023, compared to a loss of $28.2 million in the prior year period.
- Adjusted EBITDA was a loss of $23.3 million for the fourth quarter of 2023, compared to a loss of $21.7 million in the prior year period.
Retrieved on:
Monday, February 12, 2024
SAN JOSE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 44th Annual TD Cowen Health Care Conference in Boston.
Key Points:
- SAN JOSE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 44th Annual TD Cowen Health Care Conference in Boston.
- Management is scheduled to present on Tuesday, March 5 at 12:50 p.m. Eastern Time.
- A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com .
- The webcasts will be archived and available for replay for at least 90 days after the event.
Total revenue for the fourth quarter of 2023 is expected to be in the range of $43.3 million to $43.6 million, compared to $23.8 million in the prior year period.
Key Points:
- Total revenue for the fourth quarter of 2023 is expected to be in the range of $43.3 million to $43.6 million, compared to $23.8 million in the prior year period.
- Fiscal year 2023 revenue is expected to be approximately $135.9 million to $136.2 million, representing growth of approximately 81% to 82% compared to the prior year period.
- The Company’s management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- The preliminary results included in this press release are unaudited and remain subject to adjustment.
Retrieved on:
Monday, November 13, 2023
SAN JOSE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 35th Annual Piper Sandler Healthcare Conference in New York City.
Key Points:
- SAN JOSE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 35th Annual Piper Sandler Healthcare Conference in New York City.
- Management is scheduled to present on Wednesday, November 29 at 1:30 p.m. Eastern Time.
- A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com .
- The webcasts will be archived and available for replay for at least 90 days after the event.
Retrieved on:
Wednesday, November 1, 2023
International,
EBITDA,
GAAP,
Health,
Research,
Prostate cancer,
IDE,
Growth,
Marketing,
Total,
Investment,
SAN,
Acceleration,
Pharmaceutical industry,
Video game,
Bank,
Broadcasting,
Aquablation therapy U.S. handpiece and consumable revenue for the third quarter of 2023 was $17.0 million, an increase of 113% compared to the prior year period.
Key Points:
- U.S. handpiece and consumable revenue for the third quarter of 2023 was $17.0 million, an increase of 113% compared to the prior year period.
- U.S. system revenue for the third quarter of 2023 was $13.5 million, an increase of 37% compared to the prior year period.
- Operating expenses in the third quarter of 2023 were $44.5 million, compared with $32.3 million in the prior year period.
- For more information about the Company’s use of non-GAAP financial measures, please see the section below titled “Use of Non-GAAP Financial Measures (Unaudited).”
PROCEPT BioRobotics will host a conference call to discuss the third quarter 2023 financial results on Wednesday, November 1, 2023, at 4:30 p.m. Eastern Time.
SAN JOSE, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2023 after market close on Wednesday, November 1, 2023.
Key Points:
- SAN JOSE, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2023 after market close on Wednesday, November 1, 2023.
- The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
- Investors interested in listening to the conference call may do so by following one of the below links:
Webcast link for interested listeners:
